Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

Materials and methods are described for forming self-assembled peptoid structures that are extremely stable, crystalline, free-standing and self-repairing are described. Based on the peptoid design, peptoid membranes in a 2D arrangement were able to roll into single-walled nanotubes with tunable sizes, diameters, thicknesses and stiffnesses as well as tailorable functions result. Crystalline nanomaterials made through this facile solution crystallization and anisotropic formation process are highly tailorable and exhibit a number of properties advantageous for applications such as water decontamination, cellular adhesion, imaging, surface coating, biosensing, energy conversion, biocatalysis or other applications.

The disclosure is generally related to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can target multiple classes of immune cells. Methods of making and using the nanoparticles are also provided herein. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen, and a second antigen that is a major histocompatibility complex type II (MHC-II) antigen.

A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof. A fusion protein based on the heavy chain of human ferritin is de-scribed, which includes at the N terminus of the protein at least one metalloproteinase cleavage sequence and a modified PAS polypeptide that acts as a masking polymer that in-creases the protein drug stability, as well as a nanoparticle composed of multiple monomers of said fusion protein, a nucleic acid encoding for said fusion protein, and diagnostic and therapeutic applications thereof.

The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.

The invention provides nanocages, and in particular to protein nanocages, and especially ferritin nanocages. The invention extends to variant ferritin polypeptides and their encoding nucleic acids, mutant ferritin nanocages, and their uses in diagnostics and drug delivery, as well as in phenotypic screens in drug development.

The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles, and more particularly, to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles formed in such a way that 5-cholanic acid or polycaprolactone binds to a hydrophobic moiety of hyaluronic acid through self-assembly in an aqueous solution state. The pharmaceutical composition for preventing or treating an inflammatory disease or a metabolic disease, which includes hyaluronic acid nanoparticles, according to the present invention reduces body weight, lowers food intake, has an effect of reducing blood glucose as a result of a glucose tolerance test (GTT), and has an effect of reducing insulin resistance, inflammatory inducers (NF-B, IL-1, CD44, TNF-, NLRP3 inflammasome, and the like), and macrophage tissue infiltration, and thus may be effectively used as a pharmaceutical composition for preventing or treating inflammatory diseases or metabolic diseases.

The present disclosure relates to PD1-specific aptamers and methods of treating cancer.

This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described.

The invention discloses the use of single-stranded RNA toeholds of different lengths to promote the re-association of various RNA-DNA hybrids, which results in activation of multiple split functionalities inside human cells. Previously designed RNA/DNA nanoparticles employed single-stranded DNA toeholds to initiate re-association. The use of RNA toeholds is advantageous because of the simpler design rules, the shorter toeholds, and the smaller size of the resulting nanoparticles compared to the same hybrid nanoparticles with single-stranded DNA toeholds. Moreover, the co-transcriptional assemblies result in higher yields for hybrid nanoparticles with ssRNA toeholds.